First! Review of Diclofenac Sodium Sustained Release Tablets

On January 19, Hyundai pharmaceutical announced that its holding subsidiary zhijunpingshan had received the approval document for supplementary application of diclofenac sodium sustained release tablets (0.1g) approved and issued by the State Food and drug administration, and approved the drug to pass the quality and efficacy consistency evaluation of generic drugs Diclofenac sodium sustained-release tablet is a non steroidal anti-inflammatory and analgesic drug, which is mainly applied to acute and chronic arthritis, acute and chronic ankylosing spondylitis, periarthritis of shoulder, bursitis, tendinitis and tenosynovitis, lumbago, sprain, strain and other soft tissue injuries, acute gout, dysmenorrhea or appendicitis, toothache and postoperative pain The original product of the drug is diclofenac sodium sustained-release tablets (0.1g) of Novartis, with the trade name of "Voltaren".